Sergio Bagnato1, Maria Enza D'Ippolito2, Cristina Boccagni3, Antonio De Tanti4, Lucia Francesca Lucca5, Valeria Pingue6, Valentina Colombo7, Francesca Rubino3, Maria Andriolo8. 1. Unit of Neurophysiology and Unit for Severe Acquired Brain Injuries, Rehabilitation Department, Giuseppe Giglio Foundation, Cefalù, Italy. sergiobagnato@gmail.com. 2. Molecular Biology Laboratory, Giuseppe Giglio Foundation, Cefalù, Italy. 3. Unit of Neurophysiology and Unit for Severe Acquired Brain Injuries, Rehabilitation Department, Giuseppe Giglio Foundation, Cefalù, Italy. 4. Cardinal Ferrari Center, Fontanellato, Italy. 5. RAN (Research in Advanced Neuro-Rehabilitation), S. Anna Institute, Crotone, Italy. 6. Neurorehabilitation and Spinal Units, ICS Maugeri, Institute of Pavia, Pavia, Italy. 7. Montecatone Rehabilitation Institute, Imola, Italy. 8. Clinical Pathology Laboratory, Provincial Health Authority of Caltanissetta, Caltanissetta, Italy.
Abstract
BACKGROUND: Intracranial hematomas (IHs) occur commonly after severe traumatic brain injury, but their effects on outcomes in patients with prolonged disorders of consciousness (DoC) following coma (i.e., unresponsive wakefulness syndrome and minimally conscious state) are unknown. METHODS: In this multicenter longitudinal study, we compared clinical outcomes and serum neurofilament light chain (NFL) levels of 52 patients with traumatic DoC with (n = 35) and without (n = 17) IH in the acute phase. Patients were evaluated with the Coma Recovery Scale-Revised (CRS-R) at enrollment (1-3 months post-injury) and with the CRS-R, extended Glasgow Outcome Scale (GOSE), and Functional Independence Measure (FIM) at 6 months post-injury. At the same timepoints, serum NFL levels were compared between patients with and without IHs and with those of 52 sex- and age-matched healthy controls. RESULTS: Patients with and without IH did not differ in terms of DoC or CRS-R scores at admission, or clinical outcomes (death, unresponsive wakefulness syndrome, minimally conscious state, or emergence from minimally conscious state) or CRS-R, GOSE, or FIM scores 6 months post-injury. NFL levels were significantly higher in patients than in controls at admission and 6 months post-injury (both p < 0.0001), but they did not differ between patients with and without IH. CONCLUSIONS: This study showed that IHs do not affect clinical outcomes or markers of axonal degeneration in patients with traumatic DoC.
BACKGROUND: Intracranial hematomas (IHs) occur commonly after severe traumatic brain injury, but their effects on outcomes in patients with prolonged disorders of consciousness (DoC) following coma (i.e., unresponsive wakefulness syndrome and minimally conscious state) are unknown. METHODS: In this multicenter longitudinal study, we compared clinical outcomes and serum neurofilament light chain (NFL) levels of 52 patients with traumatic DoC with (n = 35) and without (n = 17) IH in the acute phase. Patients were evaluated with the Coma Recovery Scale-Revised (CRS-R) at enrollment (1-3 months post-injury) and with the CRS-R, extended Glasgow Outcome Scale (GOSE), and Functional Independence Measure (FIM) at 6 months post-injury. At the same timepoints, serum NFL levels were compared between patients with and without IHs and with those of 52 sex- and age-matched healthy controls. RESULTS: Patients with and without IH did not differ in terms of DoC or CRS-R scores at admission, or clinical outcomes (death, unresponsive wakefulness syndrome, minimally conscious state, or emergence from minimally conscious state) or CRS-R, GOSE, or FIM scores 6 months post-injury. NFL levels were significantly higher in patients than in controls at admission and 6 months post-injury (both p < 0.0001), but they did not differ between patients with and without IH. CONCLUSIONS: This study showed that IHs do not affect clinical outcomes or markers of axonal degeneration in patients with traumatic DoC.
Authors: Steven Laureys; Gastone G Celesia; Francois Cohadon; Jan Lavrijsen; José León-Carrión; Walter G Sannita; Leon Sazbon; Erich Schmutzhard; Klaus R von Wild; Adam Zeman; Giuliano Dolce Journal: BMC Med Date: 2010-11-01 Impact factor: 8.775
Authors: Joseph T Giacino; Douglas I Katz; Nicholas D Schiff; John Whyte; Eric J Ashman; Stephen Ashwal; Richard Barbano; Flora M Hammond; Steven Laureys; Geoffrey S F Ling; Risa Nakase-Richardson; Ronald T Seel; Stuart Yablon; Thomas S D Getchius; Gary S Gronseth; Melissa J Armstrong Journal: Arch Phys Med Rehabil Date: 2018-08-08 Impact factor: 3.966
Authors: E R Zanier; D Refai; G J Zipfel; T Zoerle; L Longhi; T J Esparza; M L Spinner; R J Bateman; D L Brody; N Stocchetti Journal: J Neurol Neurosurg Psychiatry Date: 2010-06-22 Impact factor: 10.154
Authors: Joseph T Giacino; S Ashwal; N Childs; R Cranford; B Jennett; D I Katz; J P Kelly; J H Rosenberg; J Whyte; R D Zafonte; N D Zasler Journal: Neurology Date: 2002-02-12 Impact factor: 9.910
Authors: Patrick Garland; Matt Morton; Ardalan Zolnourian; Andrew Durnford; Ben Gaastra; Jamie Toombs; Amanda J Heslegrave; John More; Henrik Zetterberg; Diederik O Bulters; Ian Galea Journal: Brain Date: 2021-04-12 Impact factor: 13.501